Cargando…

Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial

INTRODUCTION: Cardiovascular disease is a leading cause of death globally, responsible for nearly 18 million deaths worldwide in 2017. Medications to reduce the risk of cardiovascular events are prescribed based on evidence from clinical trials which explore treatment effects in an indicated sample...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baptiste, Paris J, Wong, Angel Y S, Schultze, Anna, Cunnington, Marianne, Mann, Johannes F E, Clase, Catherine, Leyrat, Clémence, Tomlinson, Laurie A, Wing, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905982/ https://www.ncbi.nlm.nih.gov/pubmed/35260450 http://dx.doi.org/10.1136/bmjopen-2021-051907

Ejemplares similares

Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care
por: Bidulka, Patrick, et al.
Publicado: (2020)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

Clinical trial update: focus on the ONTARGET study
por: Fitchett, David
Publicado: (2007)

Renal protection in diabetes: lessons from ONTARGET(®)
por: Ritz, Eberhard, et al.
Publicado: (2010)

Results of the ONTARGET and TRANSCEND studies: an update and discussion
por: Fitchett, David
Publicado: (2009)

Cardiovascular risk reduction by reversing endothelial dysfunction:ARBs, ACE inhibitors, or both? Expectations from The ONTARGET Trial Programme
por: Ruilope, Luis Miguel, et al.
Publicado: (2007)

Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: a cohort study of 3.7 million people
por: Dambha-Miller, Hajira, et al.
Publicado: (2022)

OnTarget: in silico design of MiniPromoters for targeted delivery of expression
por: Fornes, Oriol, et al.
Publicado: (2023)

Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD)
por: Grimaldi-Bensouda, Lamiae, et al.
Publicado: (2016)

Mechanisms by which angiotensin-receptor blockers increase ACE2 levels
por: Ferrario, Carlos M., et al.
Publicado: (2020)

Evaluation of routinely collected records for dementia outcomes in UK: a prospective cohort study
por: Hayat, Shabina, et al.
Publicado: (2022)

The Efficacy of Angiotensin Receptor-Neprilysin Inhibitor Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Post Myocardial Infarction: A Meta-Analysis
por: Kotak, Sohny, et al.
Publicado: (2023)

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
por: Chae, Young Kwang, et al.
Publicado: (2013)

A Gene Variant in CERS2 Is Associated with Rate of Increase in Albuminuria in Patients with Diabetes from ONTARGET and TRANSCEND
por: Shiffman, Dov, et al.
Publicado: (2014)

Common Methods for Handling Missing Data in Marginal Structural Models: What Works and Why
por: Leyrat, Clémence, et al.
Publicado: (2020)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Comparison of Outcomes Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Myocardial Infarction: A Meta-Analysis
por: Escobar, Johao, et al.
Publicado: (2023)

Weighting of risk factors for low birth weight: a linked routine data cohort study in Wales, UK
por: Bandyopadhyay, Amrita, et al.
Publicado: (2023)

Biochemical monitoring after initiation of aldosterone antagonist therapy in users of renin–angiotensin system blockers: a UK primary care cohort study
por: Sinnott, Sarah-Jo, et al.
Publicado: (2017)

Association between multimorbidity and socioeconomic deprivation on short-term mortality among patients with diffuse large B-cell or follicular lymphoma in England: a nationwide cohort study
por: Smith, Matthew James, et al.
Publicado: (2021)

Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction
por: Ko, Dennis, et al.
Publicado: (2019)

Stopping versus continuing renin–angiotensin–system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care data
por: Janse, Roemer J, et al.
Publicado: (2022)

Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study
por: Hibbitts, S, et al.
Publicado: (2008)

Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data
por: Hall, P S, et al.
Publicado: (2015)

Use of routine death and illness surveillance data to provide insight for UK pandemic planning: lessons from COVID-19
por: Clough, Helen E, et al.
Publicado: (2021)

Epidemiology of major lower limb amputation using routinely collected electronic health data in the UK: a systematic review protocol
por: Meffen, Anna, et al.
Publicado: (2020)

An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations
por: Wild, Philipp S., et al.
Publicado: (2020)

Should ACE Inhibitors and Angiotensin Receptor Blockers Be Withdrawn in the Current Setting of COVID-19 Infection?
por: Manga, Pravin
Publicado: (2020)

Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers
por: Lee, Ivan T., et al.
Publicado: (2020)

ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19
por: Wang, Yueying, et al.
Publicado: (2020)

ACE Inhibitor/Angiotensin Receptor Blocker Use Patterns in Advanced CKD and Risk of Kidney Failure and Death
por: Arora, Nayan, et al.
Publicado: (2020)

Evidence of potential bias in a comparison of β blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study
por: Dong, Yaa-Hui, et al.
Publicado: (2017)

Prescription of renin–angiotensin system blockers and risk of acute kidney injury: a population-based cohort study
por: Mansfield, Kathryn E, et al.
Publicado: (2016)

Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study
por: Parit, Rahul, et al.
Publicado: (2021)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease
por: ElAbd, Rawan, et al.
Publicado: (2021)

RU28318, an Aldosterone Antagonist, in Combination with an ACE Inhibitor and Angiotensin Receptor Blocker Attenuates Cardiac Dysfunction in Diabetes
por: Benter, Ibrahim F., et al.
Publicado: (2013)

Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women
por: Bea, Jennifer W., et al.
Publicado: (2018)

Reply: ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19
por: Amat-Santos, Ignacio J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_62pdkodqnhcfeg11g6hv7ktp7s